Induction chemotherapy and concurrent chemoradiotherapy for locoregionally advanced head and neck cancer : a multi-institutional phase II trial investigating three radiotherapy dose levelsSALAMA, J. K; STENSON, K. M; VOKES, E. E et al.Annals of oncology. 2008, Vol 19, Num 10, pp 1787-1794, issn 0923-7534, 8 p.Article

A Phase II trial of axitinib in patients with various histologic subtypes of advanced thyroid cancer: long-term outcomes and pharmacokinetic/pharmacodynamic analysesCOHEN, E. E. W; TORTORICI, M; KIM, S et al.Cancer chemotherapy and pharmacology. 2014, Vol 74, Num 6, pp 1261-1270, issn 0344-5704, 10 p.Article

Phase II trial of pemetrexed-based induction chemotherapy followed by concomitant chemoradiotherapy in previously irradiated patients with squamous cell carcinoma of the head and neckVILLAFLOR, V. M; HARAF, D; SEIWERT, T et al.Annals of oncology. 2011, Vol 22, Num 11, pp 2501-2507, issn 0923-7534, 7 p.Article

Oral cavity tumors in younger patients show a poor prognosis and do not contain viral RNABRÄGELMANN, J; DAGOGO-JACK, I; BIEGING, K et al.Oral oncology (1997). 2013, Vol 49, Num 6, pp 525-533, issn 1368-8375, 9 p.Article

A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4NO-1 head and neck cancersSALAMA, J. K; HARAF, D. J; STENSON, K. M et al.Annals of oncology. 2011, Vol 22, Num 10, pp 2304-2309, issn 0923-7534, 6 p.Article

Outcomes of induction chemotherapy followed by concurrent chemoradiation for nasopharyngeal carcinomaGOLDEN, D. W; RUDRA, S; WITT, M. E et al.Oral oncology (1997). 2013, Vol 49, Num 3, pp 277-282, issn 1368-8375, 6 p.Article

A phase I study of sirolimus and bevacizumab in patients with advanced malignanciesCOHEN, E. E. W; SHARMA, M. R; JANISCH, L et al.European journal of cancer (1990). 2011, Vol 47, Num 10, pp 1484-1489, issn 0959-8049, 6 p.Article

A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neckSEIWERT, T. Y; FAYETTE, J; COHEN, E. E. W et al.Annals of oncology. 2014, Vol 25, Num 9, pp 1813-1820, issn 0923-7534, 8 p.Article

Sorafenib Dose Escalation Is Not Uniformly Associated With Blood Pressure Elevations in Normotensive Patients With Advanced MalignanciesKAROVIC, S; WEN, Y; COHEN, E. E. W et al.Clinical pharmacology and therapeutics. 2014, Vol 96, Num 1, pp 27-35, issn 0009-9236, 9 p.Article

A phase I dose escalation study of Ad GV.EGR.TNF.11 D (TNFerade™ Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiationSEIWERT, T. Y; DARGA, T; WEICHSELBAUM, R. R et al.Annals of oncology. 2013, Vol 24, Num 3, pp 769-776, issn 0923-7534, 8 p.Article